Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,891 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Patients Clear all
Completed Not applicable Interventional

Personal Web Page In Clinical Trial Participant Education

NCT03887091
View directory record Official record
Conditions
Prostate Cancer, Kidney Cancer, Genitourinary Cancer
Interventions
Postwire
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 7, 2019 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 1 Interventional

BN83495 in Prostate Cancer

NCT00790374
View directory record Official record
Conditions
Prostate Cancer
Interventions
BN83495 (Cohort 1), BN83495 (Cohort 2), BN83495 (Cohort 3)
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland • Durham, North Carolina • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT00005044
View directory record Official record
Conditions
Prostate Cancer
Interventions
Casodex, Eulexin, LHRH agonist, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
1,579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2022
U.S. locations
241
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 181 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 30, 2026, 9:27 AM EDT
Active, not recruiting No phase listed Observational

Leveraging EA8191 to Assess AI-Augmented EHR Abstraction

NCT06561230
View directory record Official record
Conditions
Prostate Cancer
Interventions
Chart review
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 2 Interventional

Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery

NCT03515577
View directory record Official record
Conditions
Recurrent Prostate Carcinoma
Interventions
Computed Tomography, Fluciclovine F18, Gallium Ga 68-labeled PSMA-11, Laboratory Biomarker Analysis, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 30, 2026, 9:27 AM EDT
Recruiting Phase 2 Interventional

PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer

NCT07234981
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSMA-guided Salvage Radiation
Radiation
Lead sponsor
University of Nebraska
Other
Eligibility
30 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

NCT00878436
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Panobinostat, Bicalutamide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
4
States / cities
New Brunswick, New Jersey • Lake Success, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 2 Interventional Results available

Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.

NCT02213107
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide and Dutasteride or finasteride
Drug
Lead sponsor
University of Rochester
Other
Eligibility
65 Years to 99 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
2
States / cities
Rochester, New York • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 30, 2026, 9:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

NCT06236139
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Anti-STEAP1 CAR T-cells, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Cyclophosphamide, Echocardiography Test, Enzalutamide, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 30, 2026, 9:27 AM EDT
Active, not recruiting Phase 1 Interventional

Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer

NCT04943536
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
bicalutamide, Stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
Alessa Therapeutics Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 30, 2026, 9:27 AM EDT
Completed No phase listed Observational

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

NCT00874211
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma, Plasma Cell Neoplasm, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
assessment of therapy complications
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years
Enrollment
3,571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
451
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 302 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 30, 2026, 9:27 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

NCT04989946
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, pTVG-AR, Nivolumab, Cemiplimab, Fianlimab, FLT PET/CT
Drug · Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 2 Interventional Results available

Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer

NCT05653856
View directory record Official record
Conditions
Metastasis From Malignant Tumor of Prostate (Disorder)
Interventions
64Cu-PSMA I&T
Drug
Lead sponsor
Curium US LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
9
States / cities
New Haven, Connecticut • Hines, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 30, 2026, 9:27 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

NCT04145375
View directory record Official record
Conditions
mCRPC
Interventions
ZEN003694, Enzalutamide
Drug
Lead sponsor
Zenith Epigenetics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 1 Interventional

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

NCT03199586
View directory record Official record
Conditions
Breast Cancer, Pancreas Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Esophagus Cancer, Liver Cancer, Ovary Cancer, Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies
Interventions
NP-G2-044
Drug
Lead sponsor
Novita Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Scottsdale, Arizona • Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 2 Interventional

Study of Irofulven in Patients With Hormone-refractory Prostate Cancer

NCT00124566
View directory record Official record
Conditions
Prostate Cancer
Interventions
Irofulven, Prednisone, Mitoxantrone, Capecitabine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
29
States / cities
Hot Springs, Arkansas • Jonesboro, Arkansas • Greenbrae, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 1 Interventional

Diet Effect on Cancer Treatment Outcome

NCT05410002
View directory record Official record
Conditions
Cancer Breast, Cancer Prostate
Interventions
Dietary Supplement: N-111, Placebo
Dietary Supplement · Other
Lead sponsor
Optimal Health Research
Other
Eligibility
25 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 30, 2026, 9:27 AM EDT
Not listed Phase 1 Interventional

A Study Evaluating MM-310 in Patients With Solid Tumors

NCT03076372
View directory record Official record
Conditions
Solid Tumors, Urothelial Carcinoma, Gastric Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Prostate Adenocarcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Triple Negative Breast Cancer, Endometrial Carcinoma, Soft Tissue Sarcoma
Interventions
MM-310
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Scottsdale, Arizona • San Francisco, California • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 1 Interventional

RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

NCT00101972
View directory record Official record
Conditions
Cancer
Interventions
monoclonal antibody RAV12
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 30, 2026, 9:27 AM EDT
Terminated Not applicable Interventional

Rectal Spacer Hydrogel Before Radiation Therapy in Reducing Radiation Dose to the Rectum in Patients With Prostate Cancer

NCT05224869
View directory record Official record
Conditions
Prostate Cancer
Interventions
Medical Device Usage and Evaluation, CT simulation, Stereotactic body radiation therapy, Brachytherapy, Post-implant dosimetry scan
Device · Procedure · Radiation
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 30, 2026, 9:27 AM EDT
Terminated No phase listed Observational

Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients

NCT01076751
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
Male only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 14, 2011 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 1 Interventional

Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

NCT00620295
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
bortezomib, gemcitabine hydrochloride
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
70 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 30, 2026, 9:27 AM EDT
Terminated Phase 2 Interventional Results available

Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

NCT03152786
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Laboratory Biomarker Analysis, Propranolol Hydrochloride, Questionnaire Administration, Survey Administration
Other · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
19 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Redes III Patient Navigator Qol Study

NCT02275754
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Colorectal Cancer
Interventions
PN+LCNC, PN Only
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 30, 2026, 9:27 AM EDT